Anti-Microbial Savior BioteQ Co., Ltd.
Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. It develops technology patenting of medical fungi. The company also provides MEDIACE, an antibacterial Ingredient containing skin-friendly materials and medicinal fungal extracts. In addition, it provides customized functional face masks. The company was founded in 2018 and is… Read more
Anti-Microbial Savior BioteQ Co., Ltd. (6864) - Total Assets
Latest total assets as of June 2025: NT$201.09 Million TWD
Based on the latest financial reports, Anti-Microbial Savior BioteQ Co., Ltd. (6864) holds total assets worth NT$201.09 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anti-Microbial Savior BioteQ Co., Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how Anti-Microbial Savior BioteQ Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Anti-Microbial Savior BioteQ Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Anti-Microbial Savior BioteQ Co., Ltd.'s total assets of NT$201.09 Million consist of 81.7% current assets and 18.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 78.2% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$2.18 Million | 0.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Anti-Microbial Savior BioteQ Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anti-Microbial Savior BioteQ Co., Ltd.'s current assets represent 81.7% of total assets in 2024, an increase from 76.4% in 2021.
- Cash Position: Cash and equivalents constituted 78.2% of total assets in 2024, up from 75.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 0.9% of total assets.
Anti-Microbial Savior BioteQ Co., Ltd. Competitors by Total Assets
Key competitors of Anti-Microbial Savior BioteQ Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Anti-Microbial Savior BioteQ Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Anti-Microbial Savior BioteQ Co., Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Anti-Microbial Savior BioteQ Co., Ltd. is currently not profitable relative to its asset base.
Anti-Microbial Savior BioteQ Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.78 | 22.45 | 22.45 |
| Quick Ratio | 18.54 | 22.34 | 22.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$147.82 Million | NT$ 123.31 Million | NT$ 123.31 Million |
Anti-Microbial Savior BioteQ Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Anti-Microbial Savior BioteQ Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.55 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 93.8% |
| Total Assets | NT$248.18 Million |
| Market Capitalization | $13.58K USD |
Valuation Analysis
Below Book Valuation: The market values Anti-Microbial Savior BioteQ Co., Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Anti-Microbial Savior BioteQ Co., Ltd.'s assets grew by 93.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Anti-Microbial Savior BioteQ Co., Ltd. (2021–2024)
The table below shows the annual total assets of Anti-Microbial Savior BioteQ Co., Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$248.18 Million | +93.82% |
| 2023-12-31 | NT$128.05 Million | -29.63% |
| 2022-12-31 | NT$181.96 Million | -17.72% |
| 2021-12-31 | NT$221.16 Million | -- |